<DOC>
	<DOC>NCT00608946</DOC>
	<brief_summary>The efficacy of 8 mg of copper daily regarding cognitive function, content of beta amyloid protein in the CSF and volumetric changes in the brain will be examined in a first double-blind, placebo-controlled human clinical trial conducted in 70 patients with mild Alzheimer´s dementia.</brief_summary>
	<brief_title>Treatment With Copper in Patients With Mild Alzheimer´s Dementia</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Copper</mesh_term>
	<criteria>male or female patients between 50 and 80 years criteria of mild dementia probable Alzheimer´s dementia according to NINCDSADRDA criteria given written informed consent having a relative who can fill out questionnaire; caregiver consent free of serious and unstable somatic illness unable to give informed consent unable to take cholinesterase inhibitors unapproved medication moderate to severe Alzheimer´s disease dementia of other etiology history of alcohol, drug or medication abuse other psychiatric disorder, e. g. schizophrenia known copper and zinc storage disease known copper and zinc intolerance vegans known severe allergies or intolerances insufficient knowledge of the German language female patients of childbearing potential, pregnant or nursing patients participation in a clinical trial within the past 30 days before onset of this study severe somatic diseases and high mortality rate AST, ALT, GGT, GLDH, AP or bilirubin being a twofold above the normal range</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2008</verification_date>
	<keyword>efficacy of treatment with copper in patients with mild Alzheimer´s disease</keyword>
	<keyword>cognitive status over time</keyword>
	<keyword>CSF and volumetric data over time (1 year)</keyword>
</DOC>